Christine Turner

Associate
Full contact info

Experience

Vistagen Therapeutics – $100 Million Follow-on Offering of Common Stock, Pre-Funded Warrants and Two Tranches of Common Stock Warrants

October 4, 2023

Cooley advised the underwriters in Vistagen Therapeutics’ $100 million follow-on offering of common stock, pre-funded warrants, and two tranches of common stock warrants, with Jefferies, Stifel and William Blair acting as lead book-running managers. Vistagen Therapeutics is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system disorders. Partners Denny Won, Charlie Kim and Courtney Tygesson led the Cooley team.

Related contacts

Denny Won
Partner, San Francisco
Charlie Kim
Partner, San Diego
Courtney M.W. Tygesson
Partner, Chicago
Christine Turner
Associate, Colorado
Jesse Schulman
Associate, Washington, DC
Mike Lam
Associate, Los Angeles Santa Monica
Carley Cruea
Associate, Washington, DC

Related Practices & Industries

IGM Biosciences – $97.5 Million Follow-on Offering and Concurrent Private Placement

June 22, 2023

Cooley advised the underwriters in IGM Biosciences’ $97.5 million public offering of 9,000,000 shares of non-voting common stock and 3,187,500 shares of voting common stock, each at the public offering price of $8.00 per share, as well as a $22.5 million concurrent private placement. IGM is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with cancer, autoimmune and inflammatory diseases, and infectious diseases. Denny Won, Kristin VanderPas and Charlie Kim led the Cooley team.

Related contacts

Denny Won
Partner, San Francisco
Kristin VanderPas
Partner, San Francisco
Charlie Kim
Partner, San Diego
Christine Turner
Associate, Colorado
Mike Lam
Associate, Los Angeles Santa Monica
Ron Metzger
Paralegal Specialist, San Francisco

Related Practices & Industries

Structure Therapeutics – $185.3 Million IPO

February 9, 2023

San Francisco – February 9, 2023 Cooley advised Structure Therapeutics, a clinical-stage global biopharmaceutical company, on its $185.3 million initial public offering, including the full exercise of the underwriters’ option to purchase additional American depositary shares. Lawyers Charlie Kim, Patrick Loofbourrow, Andrew Harline and Su Lian Lu led the Cooley team.

The offering marks the first sizable US life sciences IPO this year. Structure Therapeutics will use the proceeds to develop new oral therapies for the treatment of various diseases, including those impacting the metabolic, cardiovascular and pulmonary systems. Its lead product candidate targets Type 2 diabetes and obesity.

Structure Therapeutics aims to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages structure-based drug discovery and computational chemistry expertise, enabling it to build a pipeline of product candidates. The company currently focuses on G-protein-coupled receptors as a therapeutic target class.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

Related contacts

Charlie Kim
Partner, San Diego
Patrick Loofbourrow
Partner, Singapore
Andrew Harline
Partner in Charge – Singapore, Singapore
Su Lian Lu
Special Counsel, Los Angeles Santa Monica
Xander Lee
Partner, Los Angeles Santa Monica
Jie Zhang
Partner, Hong Kong
Phil Mitchell
Partner, New York
Aaron Pomeroy
Partner, Colorado
Carlos Ramirez
Partner, San Diego
Ryan Blair
Partner, San Diego
Joshua Mates
Partner, San Francisco
Mark Ballantyne
Partner, Reston
Nicola Squire
Partner, London
Francis Wheeler
Partner, Colorado
Will Cai
Partner, Hong Kong
Thomas Welk
Senior Counsel, San Diego
Natasha Leskovsek
Of Counsel, Washington, DC
Dani Nazemian
Special Counsel, San Diego
Randy Sabett
Special Counsel, Washington, DC
Bin Wang
Special Counsel, Palo Alto
Rebecca Ross
Special Counsel, Washington, DC
Lisa Yuan
Special Counsel, Beijing
Jennifer Shanley
Special Counsel, New York
Christine Turner
Associate, Colorado
Vince Flynn
Associate, San Diego
Ivy Wang
Associate, Shanghai
Rick Jantz
Associate, Los Angeles Santa Monica
Yuan Dai
Associate, Shanghai
Cara Buchicchio
Associate, New York
Megan Drill
Associate, San Diego
Daniel Gillon
Associate, San Diego
Dionne A. Thomas
Associate, San Diego
Cristina Ferruolo
Associate, San Diego
Brian Lau
International Legal Project Manager, Hong Kong
Jessica Wade
Paralegal Specialist, San Diego
Kate Walther
Paralegal Specialist, San Diego
Lunga Su
Associate, Shanghai
Christine S. Kim
Associate, San Diego
Andy Zachrich
Associate, San Diego

Related Practices & Industries

Treace Medical Concepts – $115 Million Follow-on Offering

February 7, 2023

Cooley advised the underwriters in Treace Medical Concepts’ $115 million follow-on offering of shares of common stock. J.P. Morgan and Morgan Stanley acted as lead book-running managers for the offering, while Stifel and Truist Securities acted as book-running managers, and BTIG acted as sole manager. Treace Medical Concepts is a commercial-stage orthopedic medical device company focused on advancing the standard of care for the surgical management of bunion deformities. Partners Charlie Kim, David Peinsipp, Kristin VanderPas and Denny Won led the Cooley team.

Related contacts

Charlie Kim
Partner, San Diego
David Peinsipp
Partner, San Francisco
Kristin VanderPas
Partner, San Francisco
Denny Won
Partner, San Francisco
Peter A. Haddad
Associate, San Diego
Christine Turner
Associate, Colorado

Related Practices & Industries

Arcutis Biotherapeutics – $172.5 Million Follow-on Offering

August 24, 2022

Cooley advised the underwriters in Arcutis Biotherapeutics’ $172.5 million follow-on offering of 8,625,000 shares of common stock at a public offering price of $20.00 per share. Arcutis is a biopharmaceutical company developing and commercializing innovative treatments for immuno-dermatological diseases. Partners Denny Won, Kristin VanderPas, Charlie Kim and Dave Peinsipp led the Cooley team.

Related contacts

Denny Won
Partner, San Francisco
Kristin VanderPas
Partner, San Francisco
Charlie Kim
Partner, San Diego
David Peinsipp
Partner, San Francisco
Christine Turner
Associate, Colorado
Madison (JJ) Meng
Associate, San Francisco
Mike Lam
Associate, Los Angeles Santa Monica
Lawrence Traylor
Associate, Los Angeles Santa Monica
Kate Walther
Paralegal Specialist, San Diego

Related Practices & Industries

View more

Memberships & affiliations

New York State Bar Association